Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 42, n° 5P1
pages 796-802 (mai 2000)
Doi : 10.1067/mjd.2000.103983
Clearance is not a realistic expectation of psoriasis treatment

Sami N. Al-Suwaidan, MDa, Steven R. Feldman, MD, PhDb
Riyadh, Saudi Arabia, and Winston-Salem, North Carolina 
From the Department of Dermatology, College of Medicine, King Saud University, Riyadh,a and the Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem.b 


Background: Psoriasis is a disease with many manifestations for which numerous treatments are available. Objective: The purpose of this article is to assess whether complete clearance is a realistic expectation given the currently available treatments for psoriasis. Methods: Clinical trials of the treatment of psoriasis were identified from the medical literature, and the reported rates of clearance were compared. Results: The percentage of patients who experienced complete clearing of their psoriasis varied with the different monotherapy treatments from 2% with tazarotene gel to a maximum of 86% with narrow-band UVB. Combinations of systemic retinoids (etretinate, acitretin) and photochemotherapy (PUVA) attained the maximum reported clearance rate as combination therapy. Conclusion: The new treatments available for psoriasis give physicians new opportunity to control the severity of psoriasis. Despite the availability of novel treatments for psoriasis, complete clearing of psoriasis is obviously not a realistic expectation of topical treatment. Phototherapy and systemic therapy provide greater improvement, but studies rarely report complete clearing of the disease as an endpoint. At this time, optimal therapy consists of using combinations of different treatments to obtain short-term improvement and long-term control of the disease. (J Am Acad Dermatol 2000;42:796-802.)

The full text of this article is available in PDF format.

 Reprint requests: Steven R. Feldman, MD, PhD, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071.

© 2000  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline